Topic: class action

Allegations that AbbVie hired nurse "ambassadors" to boost Humira prescriptions have sparked a second shareholder lawsuit.

Takeda offloaded cancer assets, AstraZeneca formed drug discovery JV in China, Biocon's Herceptin biosimilar plant cleared FDA.

Endo received good news this week in a lawsuit alleging wrongdoing in how it marketed its testosterone drug Testim.

In a temporary break from its corporate drama, Sinovac posted positive topline data from a phase 3 study of its chickenpox vaccine.

With another win, Bayer and Johnson & Johnson are now three for three in fending off lawsuits over the bleeding risks of blockbuster Xarelto.

AbbVie is in court facing the first of 4,100 defendants in a class action alleging its testosterone drug AndroGel caused cardiovascular problems.

A federal judge hearing the bellwether lawsuit for "low-T" drug marketing decided the plaintiff’s case was suffering from a lack of support for some of its claims.

Allergan is facing potential fallout from shareholders who say Allergan’s share price has been stung by questionable generics pricing.

Sanofi's vaccines unit has settled a class-action suit that claimed the company leveraged its heavyweight status in the field to knock back a rival meningococcal jab from Novartis.

Since dodging a hostile buyout attempt from generics maker Mylan, Perrigo hasn’t been doing so hot. And some of the company’s shareholders aren’t pleased.